PSA Detection Service

Prostate specific antigen (PSA) is an organ-specific biomarker that has been approved by the FDA for prostate cancer screening. PSA is often tested as a biomarker in prostate cancer and prostate disease researches. Creative BioMart Biomarker provides fast and sensitive testing services for total PSA and free PSA. The service is only for research purposes and not for clinical purposes.

PSA Testing
Analyte: PSA
Synonyms: prostate specific antigen, gamma-seminoprotein, kallikrein-3, KLK3
Sample Type: cell culture supernatants, plasma, serum and other biological fluids
Assay Platform: ELISA, CLIA
Biomarker Application Area: prostate cancer
* Perform three replicate tests on each sample, and include appropriate controls in each assay.

Assay Background

Figure 1. PSA (Tkac, et al. 2019)

PSA is a glycoprotein usually produced by prostate epithelial cells and exists in the blood in different forms. Most PSA binds to serum protease inhibitors (such as α1-antichymotripsin) to form a complex, and only a small part of PSA exists in a free or unbound state. Free PSA accounts for about 5-35% of total PSA, and percentage free PSA is lower in prostate cancer. Testing the percentage free PSA can improve the specificity of prostate cancer detection. PSA is an earlier recognized cancer biomarker, which is conducive to the early screening of prostate cancer. However, because the circulating level of PSA also appears to be elevated in in conditions such as benign prostatic hyperplasia (BPH), prostatitis, prostate biopsies and surgeries, etc., PSA has the disadvantage of insufficient specificity in the screening of prostate cancer, which may lead to overdiagnosis and overtreatment of the disease. Nevertheless, PSA is still used in the diagnosis and treatment of prostate cancer, and researchers hope to explore its combined use with other biomarkers to improve its specificity as a biomarker.

Workflow of Biomarker Detection at Creative BioMart Biomarker


Customers provide: samples, reagents/kits (reagents/kits can also be provided or purchased by our company).

We provide: remaining samples and reagents, complete experimental reports (including experimental raw data, experimental procedures, instrument and reagent information, and professional result analysis).

Test cycle: 10 working days or less.

Why Choose Creative BioMart Biomarker for PSA Detection Service?

  • High-quality technology platform
  • Creative BioMart Biomarker has established a number of technical platforms that can be used for biomarker detection. We provide ELISA and CLIA technology platforms for PSA testing, and you can choose according to your research needs.

  • Experienced experts team
  • Our experts have extensive experience in biomarker testing, and will perform each test in full accordance with standard experimental operating procedures to ensure that the test results delivered are accurate and repeatable.

  • Suitable for multiple sample types
  • Our biomarker testing service is applicable to several sample types, including serum, plasma, cell culture supernatant, etc. If your sample type is not common, you can contact us at any time to inquire about the testing service for your sample type.

  • Fast testing and reasonable price
  • We have been committed to providing customers with efficient services to ensure that the experimental results are delivered within the predetermined time. Our testing services have reasonable and competitive prices in the industry, which can help customers reduce research costs.

If you are interested in our services, please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.


  1. Saini, S. PSA and beyond: alternative prostate cancer biomarkers. Cellular Oncology. 2016, 39(2): 97-106.
  2. Duffy, M. J. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine. 2019, 58(3): 326-339.
  3. Tkac, J.; et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus.2019, 9(2): 20180077.


Contact Us


Enter your email here to subscribe